When was Seragon Pharmaceuticals founded?

Seragon Pharmaceuticals was founded in 2013 and raised its 1st funding round within a year of its incorporation.

Where is Seragon Pharmaceuticals located?

Seragon Pharmaceuticals is headquartered in San Diego, United States.

Is Seragon Pharmaceuticals a funded company?

Seragon Pharmaceuticals is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Oct 17, 2013.

When was the latest funding round of Seragon Pharmaceuticals?

Seragon Pharmaceuticals' latest funding was a $***** Series A round on Oct 17, 2013, with participation from 5 investors. Its primary sector is Oncology. In United States, the Oncology sector has seen $1.23B in funding in 2026 to date.

Where does Seragon Pharmaceuticals rank among its competitors?

Seragon Pharmaceuticals ranks 1609th amongst 3191 active competitors, of which 1091 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was C4 Therapeutics, which secured $25M in Jan, 2024.

Who are the top competitors of Seragon Pharmaceuticals?

Seragon Pharmaceuticals' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Among them, C4 Therapeutics secured the most recent funding round in January, 2024.

Seragon Pharmaceuticals - 2026 Company Profile, Funding & Competitors

Company Details

Innovating biotechnology and medicine for human and animal health solutions. The company is a research-based biopharmaceutical organization dedicated to pioneering cutting-edge discoveries. Their mission is to create lifelong value for human and animal health, making personalized healthcare accessible globally. They focus on areas like aging, metabolism, AI bioinformatics, gene therapy, and immunology, striving to develop long-term solutions. The company utilizes advanced technologies like AI platforms, multiplex aging intervention technologies, hybrid gene therapy platforms, and AI vaccine design. They are committed to global expansion, supporting initiatives for better global health and partnering with industry leaders to drive innovation in R&D. Their approach includes genomic sequencing, diagnostic research, and biomanufacturing design to develop targeted treatments and therapies. They aim to empower human health globally with a bold approach to medical history in biotech advancements.

Key Metrics

Founded Year

2013

Location

San Diego, United States

Stage

Acquired

Total Funding

$30M in 1 round

Latest Funding Round

Series A, Oct 17, 2013, $*****

Investors

Aisling Capital & 4 more

Ranked

1609^th among 3191 active competitors

Similar Companies

Jazz Pharmaceuticals & 2957 more

Exit Details

Acquired by Genentech (Jul 01, 2014)

View Seragon Pharmaceuticals' full profile

Seragon Pharmaceuticals got acquired by Genentech on Jul 01, 2014.

Click here to take a look at Seragon Pharmaceuticals's acquisition in detail

Seragon Pharmaceuticals has raised a total funding of $30M over 1 round. Its latest funding round was a Series A round on Oct 17, 2013 for $*****. 5 investors participated in its latest round. Seragon Pharmaceuticals has 5 institutional investors.

Here is the list of recent funding rounds of Seragon Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 17, 2013	6148775	Series A	4934735	6305839	3123998	1372412

Access funding benchmarks and valuations. Sign up today!

View details of Seragon Pharmaceuticals's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Seragon Pharmaceuticals include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Here is the list of Top 10 competitors of Seragon Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
6th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Tamburi Investment Partners, Vivo Capital ... & 4 others	73/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
8th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
1609th	Seragon Pharmaceuticals 2013, San Diego (United States), Acquired	Innovating biotechnology and medicine for human and animal health solutions	$30M	Aisling Capital, Topspin Fund & 3 others	32/100